{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:09:35Z","timestamp":1784549375081,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ijid.2026.108436","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T15:53:27Z","timestamp":1769442807000},"page":"108436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The risk of latent tuberculosis infection in patients with type 2 diabetes mellitus according to the use of sodium-glucose cotransporter 2 inhibitors: A national database cohort study"],"prefix":"10.1016","volume":"164","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0466-7796","authenticated-orcid":false,"given":"Chung-Shu","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Han","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Ming","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Cih","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0311-5148","authenticated-orcid":false,"given":"Chin-Chung","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2026.108436_bib0001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002152","article-title":"The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling","volume":"13","author":"Houben","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijid.2026.108436_bib0002","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1183\/13993003.01245-2015","article-title":"Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries","volume":"46","author":"Getahun","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijid.2026.108436_bib0003","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1371\/journal.pmed.0050152","article-title":"Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies","volume":"5","author":"Jeon","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijid.2026.108436_bib0004","volume":"4","author":"Restrepo","year":"2016","journal-title":"Diabetes and tuberculosis. Microbiol Spectr"},{"key":"10.1016\/j.ijid.2026.108436_bib0005","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2026.108436_bib0006","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2026.108436_bib0007","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ejhf.1473","article-title":"Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction","volume":"21","author":"Yurista","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ijid.2026.108436_bib0008","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","article-title":"Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Galpha oxidation","volume":"117","author":"Kolijn","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ijid.2026.108436_bib0009","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.2337\/db16-0058","article-title":"The Na+\/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels","volume":"65","author":"Hawley","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.ijid.2026.108436_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ijid.2026.108436_bib0011","series-title":"Global tuberculosis report 2024","year":"2024"},{"key":"10.1016\/j.ijid.2026.108436_bib0012","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jdiacomp.2017.02.018","article-title":"Diabetes Complications Severity Index (DCSI)-Update and ICD-10 translation","volume":"31","author":"Glasheen","year":"2017","journal-title":"J Diabetes Its Complications"},{"key":"10.1016\/j.ijid.2026.108436_bib0013","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1213\/ANE.0000000000002920","article-title":"Propensity score methods: theory and practice for anesthesia research","volume":"127","author":"Schulte","year":"2018","journal-title":"Anesth Analg"},{"key":"10.1016\/j.ijid.2026.108436_bib0014","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00655-2019","article-title":"The global prevalence of latent tuberculosis: a systematic review and meta-analysis","volume":"54","author":"Cohen","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijid.2026.108436_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233385","article-title":"Screening for prevalence of current TB disease and latent TB infection in type 2 diabetes mellitus patients attending a diabetic clinic in an Indian tertiary care hospital","volume":"15","author":"Dabhi","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2026.108436_bib0016","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0260-2020","article-title":"Impact of latent tuberculosis infection on health and wellbeing: a systematic review and meta-analysis","volume":"30","author":"Wong","year":"2021","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.ijid.2026.108436_bib0017","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2217\/fmb-2023-0056","article-title":"End tuberculosis by 2035: challenges ahead","volume":"18","author":"Malik","year":"2023","journal-title":"Future Microbiol"},{"key":"10.1016\/j.ijid.2026.108436_bib0018","series-title":"CADTH health technology review. Prevention of tuberculosis reactivation","author":"Brett","year":"2021"},{"key":"10.1016\/j.ijid.2026.108436_bib0019","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3855\/jidc.15839","article-title":"Prevalence and risk factors for latent tuberculosis among diabetes patients in Taiwan: a cross-sectional study","volume":"16","author":"Chang","year":"2022","journal-title":"J Infect Developing Countries"},{"key":"10.1016\/j.ijid.2026.108436_bib0020","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S1472-9792(13)70004-0","article-title":"Host-pathogen interactions in tuberculosis patients with type 2 diabetes mellitus","volume":"93","author":"Restrepo","year":"2013","journal-title":"Tuberculosis (Edinburgh, Scotland)"},{"issue":"5","key":"10.1016\/j.ijid.2026.108436_bib0021","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00203-020-01818-x","article-title":"Diabetes-associated infections: development of antimicrobial resistance and possible treatment strategies","volume":"202","author":"Akash","year":"2020","journal-title":"Arch Microbiol"},{"key":"10.1016\/j.ijid.2026.108436_bib0022","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s13238-020-00809-4","article-title":"Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis","volume":"13","author":"Jiang","year":"2022","journal-title":"Protein Cell"},{"key":"10.1016\/j.ijid.2026.108436_bib0023","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.hfc.2022.03.005","article-title":"Renoprotective effects of SGLT2 inhibitors","volume":"18","author":"Vallon","year":"2022","journal-title":"Heart Failure Clin"},{"key":"10.1016\/j.ijid.2026.108436_bib0024","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202100909RR","article-title":"SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney","volume":"36","author":"Ke","year":"2022","journal-title":"FASEB J"},{"key":"10.1016\/j.ijid.2026.108436_bib0025","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1002\/jcp.26760","article-title":"Sodium-glucose cotransporter inhibitors and oxidative stress: an update","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J Cellular Physiol"},{"key":"10.1016\/j.ijid.2026.108436_bib0026","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nri2921","article-title":"Adipokines in inflammation and metabolic disease","volume":"11","author":"Ouchi","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ijid.2026.108436_bib0027","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","article-title":"Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes","volume":"85","author":"Garvey","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.ijid.2026.108436_bib0028","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s00210-023-02685-1","article-title":"Sodium-glucose cotransporter-2 inhibitor in risk of sepsis\/septic shock among patients with type 2 diabetes mellitus-a retrospective analysis of nationwide medical claims data","volume":"397","author":"Hu","year":"2024","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"10.1016\/j.ijid.2026.108436_bib0029","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1210\/clinem\/dgac558","article-title":"Sodium-glucose cotransporter 2 inhibitors and the risk of pneumonia and septic shock","volume":"107","author":"Li","year":"2022","journal-title":"J Clin Endocrinol Metabolism"},{"key":"10.1016\/j.ijid.2026.108436_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2022.101367","article-title":"Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors","volume":"48","author":"Wu","year":"2022","journal-title":"Diabetes Metabolism"},{"key":"10.1016\/j.ijid.2026.108436_bib0031","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/s41590-021-01010-3","article-title":"Insulin signaling establishes a developmental trajectory of adipose regulatory T cells","volume":"22","author":"Li","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ijid.2026.108436_bib0032","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.cmet.2018.08.003","article-title":"Insulin receptor-mediated stimulation boosts T cell immunity during inflammation and infection","volume":"28","author":"Tsai","year":"2018","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.ijid.2026.108436_bib0033","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.immuni.2021.05.004","article-title":"Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation","volume":"54","author":"Xian","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.ijid.2026.108436_bib0034","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/resp.13338","article-title":"Metformin is associated with a lower risk of active tuberculosis in patients with type 2 diabetes","volume":"23","author":"Lin","year":"2018","journal-title":"Respirology (Carlton, Vic)"},{"key":"10.1016\/j.ijid.2026.108436_bib0035","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/00325481.2020.1793520","article-title":"Dipeptidyl peptidase-4 inhibitor treatment could decrease Klebsiella pneumoniae pneumonia in patients with type 2 diabetes","volume":"132","author":"Chen","year":"2020","journal-title":"Postgrad Med"},{"issue":"5","key":"10.1016\/j.ijid.2026.108436_bib0036","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.21037\/apm-20-278","article-title":"Effects of dipeptidyl peptidase-4 inhibitor treatment doses on tuberculosis in patients with diabetes: a long-term nationwide population-based cohort study","volume":"9","author":"Chen","year":"2020","journal-title":"Ann Palliative Med"},{"key":"10.1016\/j.ijid.2026.108436_bib0037","unstructured":"CDC, USPHS. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports 2000;49:1-51."},{"key":"10.1016\/j.ijid.2026.108436_bib0038","series-title":"Tuberculosis control manual","year":"2023"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226000718?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226000718?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:55:11Z","timestamp":1784548511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226000718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":38,"alternative-id":["S1201971226000718"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108436","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The risk of latent tuberculosis infection in patients with type 2 diabetes mellitus according to the use of sodium-glucose cotransporter 2 inhibitors: A national database cohort study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108436","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108436"}}